Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in New York

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy emphasized broad awareness of wellness principles and informed patient-provider communication. Within this context, discussions of pharmaceutical interventions focused on therapeutic benefits and general safety profiles. As medical science advances, the scope of health information must evolve to address emerging patterns of exposure and their downstream implications. One such area involves the widespread use of glucagon-like peptide-1 receptor agonists, including Ozempic, for metabolic management. While these therapies offer significant benefits, a subset of patients has reported gastrointestinal complications, notably gastroparesis—a condition characterized by delayed gastric emptying. This shift from general health education to specific exposure concerns requires careful navigation, particularly when considering legal dimensions such as the statute of limitations for filing claims in jurisdictions like New York.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. This section examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the legal considerations for affected patients in New York, including the statute of limitations. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which can mimic or exacerbate gastroparesis.

Mechanistic Pathway and Risk Context

The mechanistic pathway linking Ozempic to gastroparesis involves its effect on gastric motility. GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can lead to clinically significant gastroparesis in susceptible individuals. Postmarketing reports have highlighted risks of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for severe complications from delayed gastric emptying. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Patients are instructed to inform healthcare providers prior to any planned surgeries or procedures if they are taking Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a separate warning. Instead, it notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation due to these reactions was higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes a warning about hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific gastroparesis warning may leave patients and healthcare providers unaware of the potential for this serious condition. This gap in risk communication could be relevant in legal claims alleging inadequate warnings.

Statute of Limitations for Ozempic Claims in New York

For affected patients in New York, attorney-related considerations include the statute of limitations for product liability claims. In New York, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For claims involving harm from Ozempic, the timeline between exposure and documented harm is crucial. Patients who developed gastroparesis after starting Ozempic should document the onset of symptoms, the date of diagnosis, and any medical records linking the condition to the drug. The statute of limitations may begin to run when the patient knew or should have known that the injury was caused by Ozempic. Given that gastrointestinal symptoms can be common and may not immediately be attributed to the drug, patients should seek legal advice promptly to preserve their rights. In summary, Ozempic use is associated with a higher incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The pharmacological mechanism of delayed gastric emptying provides a plausible link. The adequacy of warnings is questionable, as the label does not specifically address gastroparesis. Patients in New York should be aware of the three-year statute of limitations and consult an attorney to evaluate their claims. The evidence underscores the need for careful monitoring of gastrointestinal symptoms in patients taking Ozempic and for clear communication of risks.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in New York?

In New York, the statute of limitations for personal injury claims, including product liability claims related to Ozempic, is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. Patients should consult an attorney promptly to preserve their rights.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is known to delay gastric emptying, which can lead to gastrointestinal adverse effects. While not explicitly listed as a separate warning, clinical trials show a higher incidence of gastrointestinal symptoms, and postmarketing reports have highlighted risks of complications like pulmonary aspiration due to delayed gastric emptying. The pharmacological mechanism provides a plausible link to gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.